BR112021018219A2 - Método de tratamento de endocardite infecciosa - Google Patents
Método de tratamento de endocardite infecciosaInfo
- Publication number
- BR112021018219A2 BR112021018219A2 BR112021018219A BR112021018219A BR112021018219A2 BR 112021018219 A2 BR112021018219 A2 BR 112021018219A2 BR 112021018219 A BR112021018219 A BR 112021018219A BR 112021018219 A BR112021018219 A BR 112021018219A BR 112021018219 A2 BR112021018219 A2 BR 112021018219A2
- Authority
- BR
- Brazil
- Prior art keywords
- infective endocarditis
- sublevel
- mic
- antibiotics
- plyss2 lysine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962822386P | 2019-03-22 | 2019-03-22 | |
| US201962832708P | 2019-04-11 | 2019-04-11 | |
| US201962849093P | 2019-05-16 | 2019-05-16 | |
| US201962898379P | 2019-09-10 | 2019-09-10 | |
| US202062965720P | 2020-01-24 | 2020-01-24 | |
| PCT/US2020/024051 WO2020198073A1 (en) | 2019-03-22 | 2020-03-20 | Method of treating infective endocarditis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018219A2 true BR112021018219A2 (pt) | 2022-01-18 |
Family
ID=72611751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018219A BR112021018219A2 (pt) | 2019-03-22 | 2020-03-20 | Método de tratamento de endocardite infecciosa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220160842A1 (https=) |
| EP (1) | EP3941504A4 (https=) |
| JP (1) | JP2022525914A (https=) |
| KR (1) | KR20210141667A (https=) |
| CN (1) | CN114025782A (https=) |
| AU (1) | AU2020244764A1 (https=) |
| BR (1) | BR112021018219A2 (https=) |
| CA (1) | CA3134154A1 (https=) |
| IL (1) | IL286389A (https=) |
| MX (1) | MX2021011469A (https=) |
| WO (1) | WO2020198073A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023023560A1 (en) * | 2021-08-17 | 2023-02-23 | Contrafect Corporation | New uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100863692B1 (ko) * | 2006-12-08 | 2008-10-15 | 울산대학교 산학협력단 | 퇴행성질환 및 염증질환에 대한 예방치료 효과를 갖는7-하이드록시-6-메톡시-1,2,3,4-테트라하이드로이소퀴놀린유도체 |
| CA2833409A1 (en) * | 2011-04-21 | 2012-10-26 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| EP2699689A4 (en) * | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| KR20210121313A (ko) * | 2012-05-09 | 2021-10-07 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| KR20200023521A (ko) * | 2012-05-09 | 2020-03-04 | 콘트라펙트 코포레이션 | 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 |
| AU2016324307B2 (en) * | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| KR20190004799A (ko) * | 2016-05-12 | 2019-01-14 | 콘트라펙트 코포레이션 | 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법 |
| CA3069679A1 (en) * | 2017-07-10 | 2019-01-17 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
-
2020
- 2020-03-20 CA CA3134154A patent/CA3134154A1/en active Pending
- 2020-03-20 CN CN202080037982.5A patent/CN114025782A/zh active Pending
- 2020-03-20 WO PCT/US2020/024051 patent/WO2020198073A1/en not_active Ceased
- 2020-03-20 JP JP2021556394A patent/JP2022525914A/ja active Pending
- 2020-03-20 MX MX2021011469A patent/MX2021011469A/es unknown
- 2020-03-20 EP EP20777214.6A patent/EP3941504A4/en active Pending
- 2020-03-20 AU AU2020244764A patent/AU2020244764A1/en not_active Abandoned
- 2020-03-20 US US17/440,916 patent/US20220160842A1/en not_active Abandoned
- 2020-03-20 KR KR1020217034201A patent/KR20210141667A/ko active Pending
- 2020-03-20 BR BR112021018219A patent/BR112021018219A2/pt unknown
-
2021
- 2021-09-14 IL IL286389A patent/IL286389A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210141667A (ko) | 2021-11-23 |
| EP3941504A4 (en) | 2022-12-07 |
| IL286389A (en) | 2021-10-31 |
| EP3941504A1 (en) | 2022-01-26 |
| US20220160842A1 (en) | 2022-05-26 |
| WO2020198073A1 (en) | 2020-10-01 |
| AU2020244764A1 (en) | 2021-10-14 |
| JP2022525914A (ja) | 2022-05-20 |
| MX2021011469A (es) | 2021-10-22 |
| CA3134154A1 (en) | 2020-10-01 |
| CN114025782A (zh) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| BR112018067906A2 (pt) | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| PH12019500242A1 (en) | 9-aminomethyl minocycline compounds and uses thereof | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
| EA202190171A1 (ru) | Применение грамотрицательных видов для лечения атопического дерматита | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| BR112021018219A2 (pt) | Método de tratamento de endocardite infecciosa | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2017010837A (es) | Dosis y metodos para administrar telavancina. | |
| PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| EA201590350A1 (ru) | Комбинации с пептидом с циклизованной основной цепью | |
| FI3038616T3 (fi) | Menetelmiä bakteremian ja osteomyeliitin hoitamiseksi oritavansiinia käyttämällä | |
| ZA202102392B (en) | Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy | |
| BR112018017167A2 (pt) | titulação de cebranopadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |